Abstract

BackgroundMild cognitive impairment (MCI) is an intermediate state between normal aging and dementia including Alzheimer’s disease. Early detection of dementia, and MCI, is a crucial issue in terms of secondary prevention. Blood biomarker detection is a possible way for early detection of MCI. Although disease biomarkers are detected by, in general, using single molecular analysis such as t-test, another possible approach is based on interaction between molecules.ResultsDifferential correlation analysis, which detects difference on correlation of two variables in case/control study, was carried out to plasma microRNA (miRNA) expression profiles of 30 age- and race-matched controls and 23 Japanese MCI patients. The 20 pairs of miRNAs, which consist of 20 miRNAs, were selected as MCI markers. Two pairs of miRNAs (hsa-miR-191 and hsa-miR-101, and hsa-miR-103 and hsa-miR-222) out of 20 attained the highest area under the curve (AUC) value of 0.962 for MCI detection. Other two miRNA pairs that include hsa-miR-191 and hsa-miR-125b also attained high AUC value of ≥ 0.95. Pathway analysis was performed to the MCI markers for further understanding of biological implications. As a result, collapsed correlation on hsa-miR-191 and emerged correlation on hsa-miR-125b might have key role in MCI and dementia progression.ConclusionDifferential correlation analysis, a bioinformatics tool to elucidate complicated and interdependent biological systems behind diseases, detects effective MCI markers that cannot be found by single molecule analysis such as t-test.Electronic supplementary materialThe online version of this article (doi:10.1186/s40364-016-0076-1) contains supplementary material, which is available to authorized users.

Highlights

  • Mild cognitive impairment (MCI) is an intermediate state between normal aging and dementia including Alzheimer’s disease

  • Differential correlation analysis Differential correlation analysis was applied to the data set with 85 miRNAs for age-matched samples of 30 controls and 23 MCI patients (Tables 1 and 2)

  • The 3570 possib le pairs from the 85 miRNAs were ranked, according to the difference of correlation coefficients between controls and MCI patients

Read more

Summary

Introduction

Mild cognitive impairment (MCI) is an intermediate state between normal aging and dementia including Alzheimer’s disease. More than half MCI patients convert to dementia in 5 years, but some MCI patients remain stable or recover to normal over time [3,4,5]. This is why early detection and treatment of MCI is incredibly important. The present study is based on the hypothesis that neurite and synapse destruction, which are pathologic processes characteristic of early stages of AD, other neurodegenerative diseases, and MCI syndrome in general, can be detected in vitro by quantitative analysis of brainenriched cell-free microRNA (miRNA) in the blood [6]. Cell-free miRNA have been shown to be stable in blood samples [10], and aberrant

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call